Developer docs
API playgroundTry for free, no card

Search company profiles

Olfera

Full company profile

uuid000eg6q

Namestring
Olfera
Websiteurl
olferatx.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Olfera is a development-stage biopharmaceutical company founded in 2022 and headquartered in Mountain View, California, that is building an olfactory-based platform for drug discovery, optimization, and delivery targeting neurological disorders. The company's core technical premise is that the olfactory system provides a direct anatomical pathway to the brain, enabling therapeutics to circumvent the blood-brain barrier — a limitation the company cites as allowing only 0.1–0.2% of injected neurological antibodies and therapeutic proteins to reach their target. The platform combines advanced screening technology and pioneering chemistry to transform existing FDA-approved and promising neurological drugs into formulations optimized for nasal administration and rapid brain uptake, with stated use cases spanning epilepsy (fast-acting drugs reaching the brain within seconds), dementia (caregiver-friendly nasal sprays), and drugs with challenging oral side-effect profiles.

The leadership team consists of five members: CEO and co-founder Parnian Lak (PharmD, PhD), CTO Renaud Renault (PhD), Chief Science Advisor Kelvin Cooper (PhD), Chief Medical Advisor Zara Patel (MD), and Drug Delivery Expert Brian Kopec (PhD). The team is structured for translational science rather than commercial operations, and the company has no disclosed products, customers, partnerships, patents, or regulatory milestones in the source material.

Olfera's business model is not yet defined in commercial terms. As a pre-clinical biotech with no marketed products, pricing, distribution channels, and revenue mechanics remain undetermined; the company has disclosed $500,000 in funding from Orbital Edge Accelerator (July 2025) and participation in the SkyDeck Berkeley accelerator (2025). Its addressable market is framed around the 15% of the global population affected by neurological disorders and the $1.7 trillion in economic costs attributable to major neurological diseases, but no segment-specific capture, licensing strategy, or go-to-market plan is publicly documented.

Short descriptiontext

Olfera is a development-stage biotech building an olfactory drug delivery platform that bypasses the blood-brain barrier to treat neurological disorders including epilepsy and dementia, serving patients and caregivers via nasal spray formulations of repurposed FDA-approved drugs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMountain View, United States
HQ citystring
Mountain View
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
olfactory drug delivery, neurological therapeutics, biopharmaceutical platform, nasal spray drugs, blood-brain barrier
Industry2 codes
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neurological Biopharmaceuticals
Social media profiles1 record
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Olfera develops a proprietary olfactory drug delivery platform that uses the olfactory system as a direct, non-invasive pathway to the brain, bypassing the blood-brain barrier. The platform enables the discovery, optimization, and delivery of neurological therapeutics by transforming existing FDA-approved and promising neurological drugs into effective, safe, and easy-to-administer treatments via advanced screening technology and pioneering chemistry. Example applications include fast-acting epilepsy drugs that reach the brain within seconds and nasal spray formulations for dementia patients and their caregivers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Currently only 0.1-0.2% of injected neurological antibodies reach their target; Olfera's platform aims to significantly improve this delivery rate
Product overview1 text field

Olfera offers a single unified olfactory drug delivery platform rather than distinct named products. This platform enables drug discovery, optimization, and delivery by leveraging the olfactory system as a pathway to the brain that bypasses the blood-brain barrier. The company specializes in transforming existing FDA-approved neurological drugs into effective, safe, and easy-to-administer treatments through advanced screening technology and pioneering chemistry. Example therapeutic applications mentioned include fast-acting drugs to halt epilepsy (potentially reaching the brain within seconds) and medications optimized for nasal spray administration for dementia patients. The platform is designed to work with all major drug modalities and addresses the limitation that only 0.1-0.2% of injected neurological antibodies and therapeutic proteins typically reach their target when delivered through conventional methods.

Product and service1 record
1Olfactory Drug Delivery Platform
CategoryNeurological Biopharmaceutical Platform
Description

A proprietary drug discovery, optimization, and delivery platform that uses the olfactory system as a direct pathway to the brain, bypassing the blood-brain barrier to transform existing FDA-approved and promising neurological drugs into non-invasive, safe, and easy-to-administer treatments. Compatible with all major drug modalities, it supports applications including fast-acting epilepsy drugs that reach the brain within seconds, dementia medications optimized for nasal spray administration, and brain delivery of drugs with challenging oral side effects. Intended for biopharmaceutical development targeting neurological conditions such as epilepsy and dementia.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Was a clinical-stage biotech specializing in intranasal/upper-nasal drug delivery to the CNS using its proprietary Precision Olfactory Delivery (POD®) technology — the most direct historical peer to Olfera's olfactory delivery thesis. Provides a useful benchmark for both the opportunity and the historical execution challenges in translating nasal CNS delivery.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics for neurodegenerative and lysosomal storage diseases, including the Enzyme Transport Vehicle (ETV) platform designed to cross the BBB and deliver biologics to the brain. Most direct comparably-sized peer pursuing engineered BBB-crossing delivery for CNS biologics.

3ArmaGen
TypeDirect peer
Description

Pre-clinical/clinical biotech developing antibody-based therapeutics that cross the BBB via receptor-mediated transcytosis using the transferrin receptor — a parallel BBB-shuttle approach to delivering biologics to the CNS, directly competing with Olfera's olfactory route thesis.

TypeBroad incumbent
Description

Commercial-stage CNS biotech (now part of Pfizer) focused on neurological and neuropsychiatric diseases including migraine, epilepsy, and rare CNS disorders — relevant as a larger incumbent that has invested in intranasal CNS delivery and provides a comparison point for commercial CNS asset value.

TypeBroad incumbent
Description

Clinical-stage gene therapy company developing AAV-based therapies for CNS diseases such as Parkinson's, Huntington's, and ALS — comparable as a platform-oriented CNS biotech tackling the BBB-delivery problem with an alternative modality (gene therapy), useful for platform-valuation triangulation.

TypeBroad incumbent
Description

Biopharma developing CNS therapeutics including Zurzuvae (postpartum depression) and epilepsy programs — comparable as a CNS-focused biotech whose commercial trajectories illustrate the value of differentiated CNS delivery / mechanism approaches.

TypeEmerging player
Description

Clinical-stage neuroscience biotech pursuing precision medicine approaches for brain diseases, combining novel targets with brain-penetrant chemistry. Comparable as a well-funded platform biotech tackling CNS indications where delivery/bioavailability is a central challenge.

TypeEmerging player
Description

Clinical-stage biopharma developing small-molecule therapies for rare neurological and developmental disorders including epilepsies and Angelman syndrome. Comparable as a CNS-focused biotech where nasal/alternative delivery could be a meaningful strategic extension.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Olfera

Neurological Biopharmaceuticalsolferatx.com

Olfera is a development-stage biotech building an olfactory drug delivery platform that bypasses the blood-brain barrier to treat neurological disorders including epilepsy and dementia, serving patients and caregivers via nasal spray formulations of repurposed FDA-approved drugs.

What Olfera does

Olfera is a development-stage biopharmaceutical company founded in 2022 and headquartered in Mountain View, California, that is building an olfactory-based platform for drug discovery, optimization, and delivery targeting neurological disorders. The company's core technical premise is that the olfactory system provides a direct anatomical pathway to the brain, enabling therapeutics to circumvent the blood-brain barrier — a limitation the company cites as allowing only 0.1–0.2% of injected neurological antibodies and therapeutic proteins to reach their target. The platform combines advanced screening technology and pioneering chemistry to transform existing FDA-approved and promising neurological drugs into formulations optimized for nasal administration and rapid brain uptake, with stated use cases spanning epilepsy (fast-acting drugs reaching the brain within seconds), dementia (caregiver-friendly nasal sprays), and drugs with challenging oral side-effect profiles.

The leadership team consists of five members: CEO and co-founder Parnian Lak (PharmD, PhD), CTO Renaud Renault (PhD), Chief Science Advisor Kelvin Cooper (PhD), Chief Medical Advisor Zara Patel (MD), and Drug Delivery Expert Brian Kopec (PhD). The team is structured for translational science rather than commercial operations, and the company has no disclosed products, customers, partnerships, patents, or regulatory milestones in the source material.

Olfera's business model is not yet defined in commercial terms. As a pre-clinical biotech with no marketed products, pricing, distribution channels, and revenue mechanics remain undetermined; the company has disclosed $500,000 in funding from Orbital Edge Accelerator (July 2025) and participation in the SkyDeck Berkeley accelerator (2025). Its addressable market is framed around the 15% of the global population affected by neurological disorders and the $1.7 trillion in economic costs attributable to major neurological diseases, but no segment-specific capture, licensing strategy, or go-to-market plan is publicly documented.

Olfera firmographics

Firmographics
Name
Olfera
Website
https://olferatx.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
Olfera is a development-stage biotech building an olfactory drug delivery platform that bypasses the blood-brain barrier to treat neurological disorders including epilepsy and dementia, serving patients and caregivers via nasal spray formulations of repurposed FDA-approved drugs.
Ownership category
akta.pro rank

Olfera industry classification

Industry
Product category
Neurological Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Olfactory drug delivery
  • Neurological therapeutics
  • Biopharmaceutical platform
  • Nasal spray drugs
  • Blood-brain barrier

Where Olfera is headquartered

Location

Headquarters

HQ city
Mountain View
HQ country
United States
HQ region
North America

Markets served

Olfera business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Marketing channels1 record

Olfera product offering

Product offering

Core offering

Olfera develops a proprietary olfactory drug delivery platform that uses the olfactory system as a direct, non-invasive pathway to the brain, bypassing the blood-brain barrier. The platform enables the discovery, optimization, and delivery of neurological therapeutics by transforming existing FDA-approved and promising neurological drugs into effective, safe, and easy-to-administer treatments via advanced screening technology and pioneering chemistry. Example applications include fast-acting epilepsy drugs that reach the brain within seconds and nasal spray formulations for dementia patients and their caregivers.

Product overview

Olfera offers a single unified olfactory drug delivery platform rather than distinct named products. This platform enables drug discovery, optimization, and delivery by leveraging the olfactory system as a pathway to the brain that bypasses the blood-brain barrier. The company specializes in transforming existing FDA-approved neurological drugs into effective, safe, and easy-to-administer treatments through advanced screening technology and pioneering chemistry. Example therapeutic applications mentioned include fast-acting drugs to halt epilepsy (potentially reaching the brain within seconds) and medications optimized for nasal spray administration for dementia patients. The platform is designed to work with all major drug modalities and addresses the limitation that only 0.1-0.2% of injected neurological antibodies and therapeutic proteins typically reach their target when delivered through conventional methods.

Differentiator

Problem solved

Functional benefit

Products and services

  • Olfactory Drug Delivery Platform A proprietary drug discovery, optimization, and delivery platform that uses the olfactory system as a direct pathway to the brain, bypassing the blood-brain barrier to transform existing FDA-approved and promising neurological drugs into non-invasive, safe, and easy-to-administer treatments. Compatible with all major drug modalities, it supports applications including fast-acting epilepsy drugs that reach the brain within seconds, dementia medications optimized for nasal spray administration, and brain delivery of drugs with challenging oral side effects. Intended for biopharmaceutical development targeting neurological conditions such as epilepsy and dementia.

Quantifiable outcome

  • Currently only 0.1-0.2% of injected neurological antibodies reach their target; Olfera's platform aims to significantly improve this delivery rate

Companies that use Olfera

Customer profile

Segments2 records

Ideal customer profiles2 records

Olfera technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Olfera partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves3 records

Expansion highlights3 records

Olfera competitors and assessment

Company assessment

Direct peers

  • Impel NeuroPharma: Was a clinical-stage biotech specializing in intranasal/upper-nasal drug delivery to the CNS using its proprietary Precision Olfactory Delivery (POD®) technology — the most direct historical peer to Olfera's olfactory delivery thesis. Provides a useful benchmark for both the opportunity and the historical execution challenges in translating nasal CNS delivery.
  • Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative and lysosomal storage diseases, including the Enzyme Transport Vehicle (ETV) platform designed to cross the BBB and deliver biologics to the brain. Most direct comparably-sized peer pursuing engineered BBB-crossing delivery for CNS biologics.
  • ArmaGen: Pre-clinical/clinical biotech developing antibody-based therapeutics that cross the BBB via receptor-mediated transcytosis using the transferrin receptor — a parallel BBB-shuttle approach to delivering biologics to the CNS, directly competing with Olfera's olfactory route thesis.

Broad incumbents

  • Biohaven Pharmaceuticals: Commercial-stage CNS biotech (now part of Pfizer) focused on neurological and neuropsychiatric diseases including migraine, epilepsy, and rare CNS disorders — relevant as a larger incumbent that has invested in intranasal CNS delivery and provides a comparison point for commercial CNS asset value.
  • Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based therapies for CNS diseases such as Parkinson's, Huntington's, and ALS — comparable as a platform-oriented CNS biotech tackling the BBB-delivery problem with an alternative modality (gene therapy), useful for platform-valuation triangulation.
  • Sage Therapeutics: Biopharma developing CNS therapeutics including Zurzuvae (postpartum depression) and epilepsy programs — comparable as a CNS-focused biotech whose commercial trajectories illustrate the value of differentiated CNS delivery / mechanism approaches.

Emerging players

  • Neumora Therapeutics: Clinical-stage neuroscience biotech pursuing precision medicine approaches for brain diseases, combining novel targets with brain-penetrant chemistry. Comparable as a well-funded platform biotech tackling CNS indications where delivery/bioavailability is a central challenge.
  • Ovid Therapeutics: Clinical-stage biopharma developing small-molecule therapies for rare neurological and developmental disorders including epilepsies and Angelman syndrome. Comparable as a CNS-focused biotech where nasal/alternative delivery could be a meaningful strategic extension.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

Olfera social profiles

Digital presence

Olfera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Olfera leadership team

Management profile

Number of profiles

Profiles5 records

Olfera funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Olfera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Olfera

What does Olfera do?

Olfera develops a proprietary olfactory drug delivery platform that uses the olfactory system as a direct, non-invasive pathway to the brain, bypassing the blood-brain barrier. The platform enables the discovery, optimization, and delivery of neurological therapeutics by transforming existing FDA-approved and promising neurological drugs into effective, safe, and easy-to-administer treatments via advanced screening technology and pioneering chemistry. Example applications include fast-acting epilepsy drugs that reach the brain within seconds and nasal spray formulations for dementia patients and their caregivers.

When was Olfera founded?

Olfera was founded in 2022. It employs 1 to 10 people.

Where is Olfera based?

Olfera is headquartered in Mountain View, United States, in the North America region.

Who are Olfera's main competitors?

Direct peers on record are Impel NeuroPharma, Denali Therapeutics and ArmaGen. Broad incumbents are Biohaven Pharmaceuticals, Voyager Therapeutics and Sage Therapeutics. Emerging players are Neumora Therapeutics and Ovid Therapeutics.

Does Olfera have an API?

No public API is recorded for Olfera.

What industry is Olfera in?

Olfera's product category is Neurological Biopharmaceuticals. Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales